COMMUNIQUÉS West-GlobeNewswire

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
16/07/2026
New initiative builds on EN3ZYME™ launch and highlights scalability of the Dapibus™ platform JUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a [...]
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
16/07/2026
One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX ® -C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in patients with secondary [...]
New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
16/07/2026
ROCKAWAY, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today [...]
Former Smith+Nephew Global Orthopaedics President Craig Gaffin Joins MedEdge Holdings as Partner
16/07/2026
Healthcare industry veteran brings more than 25 years of commercial leadership experience to help expand MedEdge's platform for acquiring, building and commercializing innovative surgical technology companies GREENWICH [...]
CDT Equity Inc. Announces Reverse Stock Split
16/07/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-10 reverse stock split of [...]
Theolytics Relocates to State-of-the-Art Facility at ARC Oxford to Drive Development of THEO-260 and Other Novel Oncolytic Immunotherapies
16/07/2026
Oxford UK, July 16th, 2026. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, announces that it has relocated to new, state-of-the-art facilities at ARC Oxford, a [...]
Diverge Health and Oakland Physician Network Services Announce Successful First-Year Partnership to Improve Quality of Care for Medicaid Patients in Michigan
16/07/2026
Deep clinical integration across 10 practices yields measurable improvements in quality outcomes and sets the stage for expanded shared savings and community health programming DETROIT, July 16, 2026 (GLOBE NEWSWIRE [...]
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
16/07/2026
CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the [...]
Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
16/07/2026
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, [...]
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
16/07/2026
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, July 16, 2026 ( [...]
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
16/07/2026
Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell’s pivotal Phase 3 clinical trial in metastatic breast cancer BriaCell Phase 3 trial featured in Nature Medicine [...]
Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio
16/07/2026
Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats TORONTO, July 16, 2026 (GLOBE [...]
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
16/07/2026
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan PHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE [...]
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
16/07/2026
STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Cronos Group Inc. to Hold 2026 Second Quarter Earnings Conference Call on August 6, 2026
16/07/2026
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 second quarter earnings conference call on Thursday, August 6, 2026 at 8:30 a.m. ET [...]
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
16/07/2026
Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulating tumor cells [...]
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
16/07/2026
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech Received [...]
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
16/07/2026
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy Programme
16/07/2026
New client programme to be supported from OXB’s FDA-approved, commercial scale viral vector manufacturing facility in Durham, North Carolina, underscoring increasing global demand for OXB’s end-to-end viral vector [...]

Pages